Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
Halberd has initiated pre-pilot trials with military veterans for its patented LDN+ drug, designed to combat PTSD and suicidal ideation. The drug aims to address PTSD and suicidal thoughts by acting as an antagonist against chemical and alcohol use disorders, while also relieving pain and anxiety. The trials involve initial participants, with plans for wider pilot and safety studies in the near future. Halberd will provide updates as the clinical trial progresses.
- None.
- None.
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation
JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks.
The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation.
Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.
To stay updated on the latest developments from Halberd, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation
Halberd Corporation (OTC PINK:HALB), a publicly traded entity on the OTC Market, adheres fully to OTC Market reporting regulations. Following its restructuring in April 2020, Halberd secured exclusive global rights to three granted patents and submitted 22 associated provisional, PCT, or utility patent applications. This strategic move aims to augment the company's value for stockholders and generate interest from potential development partners.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2024, Halberd Corporation
SOURCE: Halberd Corporation
View the original press release on accesswire.com
FAQ
What is Halberd's LDN+ drug?
What are the current trials for Halberd's LDN+ drug?
How many participants are expected in the wider pilot study for Halberd's LDN+ drug?
How can one stay updated on the latest developments from Halberd ?
What is Halberd 's stock symbol?
How can one contact Halberd for more information?
